Ahead of World Malaria Day, the World Health Organization announced a major breakthrough by prequalifying the first malaria treatment specifically designed for newborns and young infants weighing between two and five kilograms. This milestone ensures that the medicine meets global standards of quality, safety, and efficacy, while also expanding access to life-saving treatment for one of the most vulnerable patient groups.
Infant-Focused Antimalarial Therapy
As per the WHO press release, the newly prequalified drug, artemether-lumefantrine, marks the first formulation tailored specifically for infants. Previously, clinicians relied on medicines designed for older children, which increased the risk of dosing errors, side effects, and toxicity. With WHO prequalification, public health systems can now procure this safer alternative, helping to address a long-standing treatment gap affecting nearly 30 million babies born annually in malaria-endemic regions, particularly in Africa.
Dr. Tedros Adhanom Ghebreyesus, Director-General of WHO, emphasized that while malaria has historically devastated communities, recent advances in vaccines, diagnostics, and treatments are transforming outcomes. He further stressed that sustained political and financial commitment remains essential to eliminate malaria globally.
New Diagnostic Tools to Address Detection Gaps
In addition to treatment advances, WHO prequalified three new rapid diagnostic tests (RDTs) on April 14, 2026. These tests respond to emerging diagnostic challenges, particularly those caused by genetic changes in the malaria parasite.
Traditionally, most RDTs detect the HRP2 protein produced by Plasmodium falciparum. However, in several regions, including parts of the Horn of Africa, parasite strains have lost the gene responsible for producing this protein. As a result, these strains evade detection, leading to false-negative results. In some areas, up to 80% of cases went undiagnosed, delaying treatment and increasing the risk of severe illness and death.
To overcome this issue, the new RDTs target an alternative protein, pf-LDH, which the parasite cannot easily eliminate. Consequently, these tests offer more reliable detection in areas where HRP2-based tests fail. WHO now recommends switching to these alternative diagnostics when more than 5% of cases are missed due to HRP2 gene deletions.
Global Campaign: A Call to Act Now
These developments coincide with the launch of the 2026 World Malaria Day campaign, titled “Driven to End Malaria: Now We Can. Now We Must.” The campaign serves as a global call to accelerate efforts, protect vulnerable populations, and invest in a malaria-free future.
Global Burden and Emerging Challenges
According to the World Malaria Report 2025, malaria remains a major global health challenge. In 2024, there were an estimated 282 million cases and 610,000 deaths, reflecting an increase compared to 2023. Although 47 countries have achieved malaria-free certification and 37 reported fewer than 1,000 cases, global progress has slowed.
Multiple factors continue to threaten gains, including drug resistance, insecticide resistance, diagnostic limitations, and declining international funding. These challenges highlight the need for sustained innovation and investment.
Progress and Future Outlook
Despite these obstacles, significant progress has been made. Since 2000, global efforts have prevented approximately 2.3 billion infections and saved 14 million lives. Furthermore, 25 countries are now rolling out malaria vaccines, protecting millions of children, while next-generation mosquito nets account for 84% of newly distributed nets.
Together, these advancements demonstrate that coordinated global action can drive meaningful change. With continued commitment, innovation, and collaboration, the goal of ending malaria is increasingly within reach.